Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Data publikacji: 24 lis 2020

Zakres stron: 38 - 43

Przyjęty: 20 gru 2019

DOI: https://doi.org/10.2478/amb-2020-0043

Słowa kluczowe

azacytidine, MDS, AML, CMML-2

© 2020 V. Varbanova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.